Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ICMT | O60725 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3424944 | 0.80 | HTT (0.55) | HTTALDH1A1NPC1RAB9ALMNA | |
| SCHEMBL9504635 | 0.79 | HTT (0.62) | HTTALDH1A1NPC1RAB9ALMNA | |
| SCHEMBL9543244 | 0.76 | HTT (0.53) | HTTALDH1A1NPC1RAB9ALMNA | |
| SCHEMBL7081392 | 0.75 | LSS (0.37) | HTTS1PR1S1PR3ALDH1A1TRPV1 | |
| SCHEMBL9157683 | 0.73 | ALDH1A1 (0.52) | HTTALDH1A1NPC1RAB9ALMNA | |
| SCHEMBL437919 | 0.72 | MAOA (0.48) | NPC1RAB9ATSHR | |
| SCHEMBL10971010 | 0.70 | MAPT (0.63) | S1PR1S1PR3TRPV1LMNATSHR | |
| SCHEMBL10971007 | 0.70 | MAPT (0.63) | S1PR1S1PR3TRPV1LMNATSHR | |
| SCHEMBL9069760 | 0.70 | HTT (0.44) | HTTALDH1A1NPC1RAB9ALMNA | |
| SCHEMBL1749601 | 0.70 | ALDH1A1 (0.55) | ALDH1A1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030149084-A1 | Cytostatic agents | AYSCOUGH ANDREW PAUL (GB) | 2003-08-07 | — | — | US | disclosed |
| US-6495597-B1 | N-FORMYL HYDROXYLAMINE DERIVATIVES | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2002-12-17 | — | — | US | disclosed |
| EP-1054861-A1 | CYTOSTATIC AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-11-29 | — | — | EP | disclosed |
| WO-1999041232-A1 | CYTOSTATIC AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149084-A1 | Cytostatic agents | MCTS1, NNMT, MMP12 | HTT 1581/4885S1PR1 1702/4885S1PR3 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.